Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults
Funded by: National Institute on Drug Abuse
Project dates: August 2019 - April 2024
Principal Investigator: Lee, Joshua D.Project dates: August 2019 - April 2024
Principal Investigator: Farabee D
Principal Investigator: Marsch L
Principal Investigator: Springer S
Principal Investigator: Waddell E
PROJECT DESCRIPTION
This study will implement evidence-based treatment in correctional settings by comparing the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons at five trial sites: New York, Connecticut, New Hampshire, Oregon, and Delaware. This study will allow providers, correctional and public health authorities, payers and policy makers’ timely and relevant data to assess the effectiveness of XR-B (as well as XR-NTX) as a potentially useful re-entry treatment option.
Abstract on NIH RePORTERRelated Publications
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD (2020). Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Journal of Substance Abuse Treatment, 128, 108389. doi: 10.1016/j.jsat.2021.108389. PMCID: PMC8384640.